These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22018617)

  • 1. Systemic reactions with aeroallergen cluster immunotherapy in a clinical practice.
    Copenhaver CC; Parker A; Patch S
    Ann Allergy Asthma Immunol; 2011 Nov; 107(5):441-7. PubMed ID: 22018617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
    Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
    Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra-rush buildup. A retrospective study.
    Cardona R; Lopez E; Beltrán J; Sánchez J
    Allergol Immunopathol (Madr); 2014; 42(2):90-5. PubMed ID: 23265265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy.
    Roy SR; Sigmon JR; Olivier J; Moffitt JE; Brown DA; Marshall GD
    Ann Allergy Asthma Immunol; 2007 Jul; 99(1):82-6. PubMed ID: 17650835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy.
    Quiralte J; Justicia JL; Cardona V; Dávila I; Moreno E; Ruiz B; García MA
    Immunotherapy; 2013 Dec; 5(12):1295-303. PubMed ID: 24283840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of rush immunotherapy to multiple aeroallergens in an adult population.
    Harvey SM; Laurie S; Hilton K; Khan DA
    Ann Allergy Asthma Immunol; 2004 Apr; 92(4):414-9. PubMed ID: 15104192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of an unusual cluster of systemic reactions to subcutaneous specific immunotherapy with respiratory allergens in one allergy center.
    Scherer K; Schindler C; Arnold A; Bach S; Bircher AJ
    Int Arch Allergy Immunol; 2012; 157(3):318-20. PubMed ID: 22056648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fungal immunotherapy in patients with allergic fungal sinusitis.
    Greenhaw B; deShazo RD; Arnold J; Wright L
    Ann Allergy Asthma Immunol; 2011 Nov; 107(5):432-6. PubMed ID: 22018615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of immunotherapy with therapeutic vaccines containing depigmented and polymerized allergen extracts.
    Casanovas M; Martín R; Jiménez C; Caballero R; Fernández-Caldas E
    Clin Exp Allergy; 2007 Mar; 37(3):434-40. PubMed ID: 17359393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective Italian survey on the safety of subcutaneous immunotherapy for respiratory allergy.
    Schiappoli M; Ridolo E; Senna G; Alesina R; Antonicelli L; Asero R; Costantino MT; Longo R; Musarra A; Nettis E; Crivellaro M; Savi E; Massolo A; Passalacqua G
    Clin Exp Allergy; 2009 Oct; 39(10):1569-74. PubMed ID: 19486027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline serum tryptase levels and adverse reactions to injection specific immunotherapy with airborne allergens: is there a relationship?
    Asero R; Farioli L; Pastorello EA
    Int Arch Allergy Immunol; 2012; 158(3):276-80. PubMed ID: 22398453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New administration routes for immunotherapy].
    Martorell Aragonés A
    Allergol Immunopathol (Madr); 2000; 28(3):93-102. PubMed ID: 10867377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cluster-immunotherapy in seasonal allergic rhinitis: safety aspects of induction therapy with depot allergoids (Purethal)].
    Hansen I; Hörmann K; Stuck BA; Schneider-Gêne S; Mösges R; Klimek L
    Laryngorhinootologie; 2003 Aug; 82(8):558-63. PubMed ID: 12915987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and characteristics of biphasic reactions after allergen immunotherapy.
    Scranton SE; Gonzalez EG; Waibel KH
    J Allergy Clin Immunol; 2009 Feb; 123(2):493-8. PubMed ID: 19064282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerated immunotherapy schedules: review of efficacy and safety.
    Cox L
    Ann Allergy Asthma Immunol; 2006 Aug; 97(2):126-37; quiz 137-40, 202. PubMed ID: 16937741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allergen immunotherapy-induced biphasic systemic reactions: incidence, characteristics, and outcome: a prospective study.
    Confino-Cohen R; Goldberg A
    Ann Allergy Asthma Immunol; 2010 Jan; 104(1):73-8. PubMed ID: 20143649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonfatal systemic reactions to subcutaneous immunotherapy: a 10-year experience.
    Ragusa FV; Passalacqua G; Gambardella R; Campanari S; Barbieri MM; Scordamaglia A; Canonica GW
    J Investig Allergol Clin Immunol; 1997; 7(3):151-4. PubMed ID: 9252872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting patients at high-risk of systemic reactions to cluster allergen immunotherapy: a pilot prospective observational study.
    Justicia JL; Barasona MJ; Serrano P; Moreno C; Guerra F
    J Investig Allergol Clin Immunol; 2007; 17(6):386-92. PubMed ID: 18088021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Side-effects of allergen-specific immunotherapy: a prospective multi-centre study.
    Winther L; Arnved J; Malling HJ; Nolte H; Mosbech H
    Clin Exp Allergy; 2006 Mar; 36(3):254-60. PubMed ID: 16499635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient dropouts before completion of optimal dose, multiple allergen immunotherapy.
    Rhodes BJ
    Ann Allergy Asthma Immunol; 1999 Mar; 82(3):281-6. PubMed ID: 10094219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.